DPH - CAS 484049-04-9
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
DPH is a potent cell permeable c-Abl activator. It binds and alters the conformation of the myristoyl binding site of c-Abl tyrosine kinase. DPH exhibits potent enzymatic and cellular activity that stimulates the activation of c-Abl and may be used in c-Abl tyrosine kinase-mediated cell signaling studies.
Publictions citing BOC Sciences Products
  • >> More
1.Quantitative Monitoring of Microphase Separation Behaviors in Cationic Liposomes Using HHC, DPH, and Laurdan: Estimation of the Local Electrostatic Potentials in Microdomains.
Suga K1, Akizaki K1, Umakoshi H1. Langmuir. 2016 Apr 19;32(15):3630-6. doi: 10.1021/acs.langmuir.5b04682. Epub 2016 Apr 6.
Microphase separation behaviors of cationic liposomes have been investigated using a pH-sensitive fluorescent probe with 4-heptadecyl-7-hydroxycoumarin (HHC), 1,6-diphenyl-1,3,5-hexatriene, and 6-lauroyl-2-dimethylaminonaphthalene, and to estimate localized electrostatic potentials. Shifts of the apparent pKa values of HHC were observed in cationic liposomes in proportion to the amount of cationic lipids. Two pKa values were obtained with 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)/3β-[N(N',N'-dimethylaminoethane)-carbamoyl] cholesterol hydrochloride (DC-Ch) liposomes, while only one pKa value was generated with either DOPC/1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or DOPC/dimethyldioctadecylammonium-bromide (DODAB) liposomes. The physicochemical membrane property analyses, focusing on membrane fluidity and membrane polarity, revealed heterogeneity among DOPC/DC-Ch liposomes. By analyzing the pH titration curves using sigmoidal fitting, the localized electrostatic potentials were estimated.
2.Pediatrician's cough and cold medication prescription for hypothetical cases - A cross-sectional multi-centric study.
Chandelia S1, Dhankar M1, Salhan M2. Saudi Pharm J. 2016 Mar;24(2):176-81. doi: 10.1016/j.jsps.2015.02.011. Epub 2015 Mar 19.
BACKGROUND: Concerns over inappropriate use of cough and cold medication (CCM) in children have been raised. In addition to being ineffective, these are now considered toxic for young children. Despite this fact studies from some regions have shown high use of these medications by physicians. However data on pediatricians and from India are negligible.
3.Decellularized fresh homografts for pulmonary valve replacement: a decade of clinical experience.
Sarikouch S1, Horke A2, Tudorache I2, Beerbaum P3, Westhoff-Bleck M4, Boethig D5, Repin O6, Maniuc L6, Ciubotaru A6, Haverich A2, Cebotari S2. Eur J Cardiothorac Surg. 2016 Mar 24. pii: ezw050. [Epub ahead of print]
OBJECTIVES: Decellularized homografts have shown auspicious early results when used for pulmonary valve replacement (PVR) in congenital heart disease. The first clinical application in children was performed in 2002, initially using pre-seeding with endogenous progenitor cells. Since 2005, only non-seeded, fresh decellularized allografts have been implanted after spontaneous recellularization was observed by several groups.
4.Optimal Hydrophobicity in ROMP-based Protein Mimics Required for siRNA Internalization.
deRonde BM, Posey ND, Otter R, Caffrey LM, Minter LM, Tew GN. Biomacromolecules. 2016 Apr 21. [Epub ahead of print]
Exploring the role of polymer structure for the internalization of biologically relevant cargo, specifically siRNA, is of critical importance to the development of improved delivery reagents. Herein, we report guanidinium-rich protein transduction domain mimics (PTDMs) based on a ring-opening metathesis polymerization scaffold containing tunable hydrophobic moieties that promote siRNA internalization. Structure-activity relationships using Jurkat T cells and HeLa cells were explored to determine how the length of the hydrophobic block and the hydrophobic side chain compositions of these PTDMs impacted siRNA internalization. To explore the hydrophobic block length, two different series of diblock copolymers were synthesized: one series with symmetric block lengths and one with asymmetric block lengths. At similar cationic block lengths, asymmetric and symmetric PTDMs promoted siRNA internalization in the same percentages of the cell population regardless of the hydrophobic block length; however, with twenty repeat units of cationic charge, the asymmetric block length had greater siRNA internalization, highlighting the non-trivial relationships between hydrophobicity and overall cationic charge.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Bcr-Abl Products

CAS 923288-90-8 Nilotinib monohydrochloride monohydrate

Nilotinib monohydrochloride monohydrate
(CAS: 923288-90-8)

Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It ...

CAS 895519-91-2 Flumatinib mesylate

Flumatinib mesylate
(CAS: 895519-91-2)

Flumatinib mesylate, a derivative of imatinib, is a multi-kinase inhibitor for c-Abl, PDGFRβ and c-Kit. It is currently in Phase I and II clinical trials in Chi...

CAS 690206-97-4 ZM306416

(CAS: 690206-97-4)

ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.

CAS 1492952-76-7 Asciminib

(CAS: 1492952-76-7)

Asciminib, also known as ABL001, is a potent and selective allosteric Bcr-Abl inhibitor. Asciminib inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.

CAS 1020172-07-9 Rebastinib

(CAS: 1020172-07-9)

DCC-2036(Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR

CAS 943319-70-8 Ponatinib

(CAS: 943319-70-8)

Ponatinib is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.

CAS 778277-15-9 GNF-5

(CAS: 778277-15-9)

CAS 859212-16-1 Bafetinib

(CAS: 859212-16-1)

Bafetinib, also known as INNO-406, is an orally bioavailable 2-phenylaminopyrimidine derivative with potential antineoplastic activity. Bafetinib specifically ...

CAS 1257628-77-5 GZD824

(CAS: 1257628-77-5)

GZD824 potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively. It also display...

CAS 778270-11-4 GNF-2

(CAS: 778270-11-4)

CAS 641571-10-0 Nilotinib

(CAS: 641571-10-0)

Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM.

CAS 854001-07-3 Dasatinib hydrochloride

Dasatinib hydrochloride
(CAS: 854001-07-3)

Dasatinib hydrochloride is a potent and dual Abl/ Src inhibitor. It inhibits c-Kit (WT)/c-Kit (D816V).

CAS 302962-49-8 Dasatinib

(CAS: 302962-49-8)

Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and...

CAS 887650-05-7 Bafetinib

(CAS: 887650-05-7)

Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor, but it does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and ...

(CAS: 1808287-83-3)

CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...

CAS 484049-04-9 DPH

(CAS: 484049-04-9)

DPH is a potent cell permeable c-Abl activator. It binds and alters the conformation of the myristoyl binding site of c-Abl tyrosine kinase. DPH exhibits potent...

CAS 260415-63-2 PD-173955

(CAS: 260415-63-2)

PD-173955 is a src tyrosine kinase inhibitor. PD173955 inhibited Bcr-Abl-dependent cell growth. PD173955 showed cell cycle arrest in G(1). PD173955 has an IC(50...

CAS 839706-07-9 GNF-7

(CAS: 839706-07-9)

GNF-7 is a type-II T315I inhibitor. GNF-7 inhibits Ack1 and germinal center kinase (GCK). GNF-7 is among the first type-II inhibitors capable of inhibiting T315...

Chemical Structure

CAS 484049-04-9 DPH

Quick Inquiry

Verification code

Featured Items